Overview

Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to confirm the efficacy and safety of rostaporfin (PHOTREX) photodynamic therapy (PDT) in the treatment of classic and occult subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).

Phase:

Phase 3

Details

Lead Sponsor:

Miravant Pharmaceuticals

Treatments:

Tin etiopurpurin